The Canadian Journal of Clinical Pharmacology found that long-acting, once-daily CONCERTA is significantly more effective than usual care with immediate release methylphenidate (IR-MPH) in achieving symptom remission in children with attention deficit hyperactivity disorder (ADHD). The study also demonstrated that the CONCERTA group experienced a significant reduction, compared to immediate release methylphenidate, in the severity of the symptoms of ADHD. At study endpoint, 44 percent of patients taking CONCERTA achieved remission compared to 16 percent of patients on IR-MPH.
But, it’s not all a bowl of cherries– adverse events were reported in 82 percent of subjects in both the CONCERTA and IR-MPH groups. The most common adverse events reported were headache, stomach pain, sleeplessness and decreased appetite. So maybe ADHD will now stand for “no Appetite Despite Headaches & Diarrhea?”
Related: Warning Urged for ADHD Drugs